MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10840-023-01575-z

Медицинская библиотека · Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2023

Comparative arrhythmia patterns among patients on tyrosine kinase inhibitors.

Wei Chen, Fazal Muhammad, Loh Alexander, Kapoor Ridhima, Gomez Sofia Elena, Shah Shayena, Rogers Albert J, Narayan Sanjiv M, Wang Paul J, Witteles Ronald M, Perino Alexander C, Cheng Paul, Rhee June-Wha, Baykaner Tina

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Tyrosine kinase inhibitors (TKIs) are widely used in the treatment of hematologic malignancies. Limited studies have shown an association between treatment-limiting arrhythmias and TKI, particularly ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. We sought to comprehensively assess the arrhythmia burden in patients receiving ibrutinib vs non-BTK TKI vs non-TKI therapies.

METHODS

We performed a retrospective analysis of consecutive patients who received long-term cardiac event monitors while on ibrutinib, non-BTK TKIs, or non-TKI therapy for a hematologic malignancy between 2014 and 2022.

RESULTS

One hundred ninety-three patients with hematologic malignancies were included (ibrutinib = 72, non-BTK TKI = 46, non-TKI therapy = 75). The average duration of TKI therapy was 32 months in the ibrutinib group vs 64 months in the non-BTK TKI group (p = 0.003). The ibrutinib group had a higher prevalence of atrial fibrillation (n = 32 [44%]) compared to the non-BTK TKI (n = 7 [15%], p = 0.001) and non-TKI (n = 15 [20%], p = 0.002) groups. Similarly, the prevalence of non-sustained ventricular tachycardia was higher in the ibrutinib group (n = 31, 43%) than the non-BTK TKI (n = 8 [17%], p = 0.004) and non-TKI groups (n = 20 [27%], p = 0.04). TKI therapy was held in 25% (n = 18) of patients on ibrutinib vs 4% (n = 2) on non-BTK TKIs (p = 0.005) secondary to arrhythmias.

CONCLUSIONS

In this large retrospective analysis of patients with hematologic malignancies, patients receiving ibrutinib had a higher prevalence of atrial and ventricular arrhythmias compared to those receiving other TKI, with a higher rate of treatment interruption due to arrhythmias.

Для цитирования: Wei Chen, Fazal Muhammad, Loh Alexander, Kapoor Ridhima, Gomez Sofia Elena, Shah Shayena, Rogers Albert J, Narayan Sanjiv M, Wang Paul J, Witteles Ronald M, Perino Alexander C, Cheng Paul, Rhee June-Wha, Baykaner Tina. Comparative arrhythmia patterns among patients on tyrosine kinase inhibitors.. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing. 2023. DOI: 10.1007/s10840-023-01575-z.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.